Technical

The Price Picture

RadNet is in a confirmed downtrend. Price sits 18.8% below the 200-day average, a second death cross printed on 2026-03-20, and the stock is trading in the bottom 21% of its 52-week range. The one-month MACD bounce is a counter-trend reflex, not a reversal.

Price snapshot

The critical chart — price vs 50/200-day SMA

Price is below the 200-day SMA by 18.8%. The five-year uptrend from the 2020 Covid low broke in early 2025; a sharp mid-2025 rally to a new all-time high of $93.65 has since unwound by nearly 40%. This is a downtrend regime.

Relative strength — RDNT vs SPY and XLV (rebased to 100)

Over three years, RDNT has crushed both the S&P 500 and the Health Care sector ETF — up 105% versus SPY +71% and XLV +9%. But the excess-return gap is narrowing fast: the RDNT-vs-SPY spread peaked near 150 points in November 2024 and has compressed to 34 points today. The leadership trade is still intact, but relative strength is bleeding.

Momentum — RSI and MACD

RSI prints 41.4 — neutral, not oversold. Despite a 30% six-month drawdown, momentum has not reached the panic zone below 30, meaning there is no technical "reset" yet. The MACD histogram flipped positive on April 14 and is currently +0.47, a short-term bounce signal — but the underlying MACD line remains deeply negative (-1.14) and has not crossed its signal line. Read as: a reflexive rally inside a downtrend.

Volume and conviction

The current drawdown has no capitulation signature. None of the six biggest volume days in the last seven years occurred during the March–April 2026 decline; they are all older events (2019 and 2023 clusters around biotech/imaging news cycles). This is a distribution-style slow bleed, not a panic low — which argues against buying the dip on the assumption that sellers are exhausted.

Volatility regime

Current 30-day realized volatility is 34.7% — in the normal-to-calm band (between the 20th and 50th percentile of a ten-year history). Vol spiked to 57% in late March during the death-cross leg but has already settled back. The market is not pricing heightened stress; option traders are treating this as a routine drawdown, not a crisis.

Technical scorecard and stance

Stance — 3-to-6 month horizon: bearish

The setup is a textbook downtrend confirmation: price below the 200-day, a second death cross in 13 months, 52-week position near the floor, no volume capitulation, and relative-strength leadership compressing. The MACD blip and RSI 41 are consistent with a counter-trend bounce — not a turn. Two levels define the next move:

• Bullish invalidation: reclaim $62 (the 50-day SMA). A decisive close above $62 would neutralize the death cross dynamic and set up a retest of the 200-day near $69. Until then, rallies are to be sold.
• Bearish confirmation: break $48.73 (the 52-week low). A weekly close below the 52w low opens the door to the $40–$44 zone — the 2023 consolidation floor and the prior golden-cross pivot.

The short-term MACD bounce argues for a grind rather than immediate collapse; absent a fundamental catalyst, expect the stock to trade between $52 and $62 before choosing a side.

Cross-check with the Numbers tab. Quant flags that EV/EBITDA rerated from ~9x to ~20x over two years while real earnings barely moved — the multiple now sits roughly 1.3 standard deviations above its long-run mean. Price action and fundamentals tell the same story from opposite ends: the tape is doing what a stretched multiple should eventually do. The downtrend is the multiple-compression cycle showing up on the chart.